These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37214204)

  • 41. It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy.
    Sheban F
    Front Immunol; 2023; 14():1183578. PubMed ID: 37359522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy.
    Le Bourgeois T; Strauss L; Aksoylar HI; Daneshmandi S; Seth P; Patsoukis N; Boussiotis VA
    Front Oncol; 2018; 8():237. PubMed ID: 30123774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment.
    Yu W; Lei Q; Yang L; Qin G; Liu S; Wang D; Ping Y; Zhang Y
    J Hematol Oncol; 2021 Nov; 14(1):187. PubMed ID: 34742349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy.
    Cazzetta V; Depierreux D; Colucci F; Mikulak J; Mavilio D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy.
    Yu M; Zeng W; Ouyang Y; Liang S; Yi Y; Hao H; Yu J; Liu Y; Nie Y; Wang T; Deng Y; Wu M
    Biomaterials; 2022 May; 284():121503. PubMed ID: 35367841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy.
    Zhu X; Zhu L; Wu Y
    Curr Protein Pept Sci; 2022; 23(9):585-601. PubMed ID: 35726423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implications of metabolism-driven myeloid dysfunctions in cancer therapy.
    Strauss L; Guarneri V; Gennari A; Sica A
    Cell Mol Immunol; 2021 Apr; 18(4):829-841. PubMed ID: 33077904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
    Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
    Front Immunol; 2020; 11():1075. PubMed ID: 32547560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reprogramming the tumor microenvironment with biotechnology.
    Kim M; Lee NK; Wang CJ; Lim J; Byun MJ; Kim TH; Park W; Park DH; Kim SN; Park CG
    Biomater Res; 2023 Jan; 27(1):5. PubMed ID: 36721212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune checkpoint inhibitors for recurrent endometrial cancer.
    Mutlu L; Harold J; Tymon-Rosario J; Santin AD
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota.
    Agrawal B
    Clin Transl Med; 2019 Aug; 8(1):23. PubMed ID: 31468283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.
    Yegutkin GG; Boison D
    Pharmacol Rev; 2022 Jul; 74(3):797-822. PubMed ID: 35738682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interplay between Immune Checkpoint Proteins and Cellular Metabolism.
    Lim S; Phillips JB; Madeira da Silva L; Zhou M; Fodstad O; Owen LB; Tan M
    Cancer Res; 2017 Mar; 77(6):1245-1249. PubMed ID: 28246276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting amino acid metabolism in cancer growth and anti-tumor immune response.
    Ananieva E
    World J Biol Chem; 2015 Nov; 6(4):281-9. PubMed ID: 26629311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
    Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
    Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity.
    Hasan MN; Capuk O; Patel SM; Sun D
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.